MedTrace Logo

Effect of the Chromium Nicotinate on Type 2 Diabetes

NCT01368328 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2011-06-07

No results posted yet for this study

Summary

The role of micronutrients in diabetes is not well understood. Studies have demonstrated the relationship between low chromium serum levels and insulin resistance. This study aims to evaluate the effect of chromium nicotinate on increasing insulin sensitivity in patients with type 2 diabetes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Chromium nicotinate

The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.

Sponsors & Collaborators

  • Universidade Federal de Goias

    lead OTHER

Principal Investigators

  • Marília Mendonça Guimarães · Faculdade de Nutrição - Universidade Federal de Goiás

  • Maria Sebastiana Silva · Faculdade de Educação Física - Universidade Federal de Goiás

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-07-31
Completion
2011-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368328 on ClinicalTrials.gov